HORMONE REPLACEMENT IN MENOPAUSAL WOMEN

更年期女性的激素替代

• 批准号: 3745466
• 负责人: S M HARMAN
• 金额: --
• 依托单位: NATIONAL INSTITUTE ON AGING
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3745466
• 关键词: aging; body composition; bone density; combination chemotherapy; drug adverse effect; endocrine pharmacology; estrogens; female; hormone therapy; human old age (65+); human subject; human therapy evaluation; oral administration; postmenopause; progestins

We are studying 30 women 65-75 years of age treated for 2 y with constant oral estrogen/low dose daily progestin (ERT) and 30 age-matched BLSA controls for bone loss (DEXA) and biochemical indices of bone turnover, plasma lipids, anthropometric indices, DEXA measures of body fat, and vaginal maturation indices. Mood, symptoms of estrogen deficiency, and side effects of hormone replacement therapy are assessed. Minor breast tenderness and vaginal bleeding are the only adverse effects observed. Treated women showed a 3.8% decrease in total cholesterol (NS) with a 16% increase in HDL and a 17% decrease in LDL (both p<0.001), and no significant change in plasma triglycerides. DEXA scans revealed a decrease in percent body fat (p<0.03) and increases in lean body mass (p<0.03) and bone mineral density (lumbar spine +7%; femoral trochanter +9%, both p<0.01). Data suggest that ERT in older postmenopausal women improves metabolic function and results in favorable changes in body composition. We find a favorable risk/benefit ratio for ERT in older postmenopausal women.

我们正在对30名年龄在65-75岁之间的女性进行为期2年的治疗。 恒定口服雌激素/低剂量每日孕激素(ERT)和30名年龄匹配的人 BLSA控制骨丢失(DEXA)和骨生化指标 周转率、血脂、人体测量指数、人体地塞米松测量 脂肪和阴道成熟指数。情绪，雌激素的症状 对激素替代疗法的不足和副作用进行评估。 唯一的不良反应是轻微的乳房压痛和阴道出血。 观察到效果。接受治疗的女性总人数下降了3.8% 胆固醇(NS)，高密度脂蛋白增加16%，低密度脂蛋白下降17% (P&lt；0.001)，血浆甘油三酯没有显著变化。地塞米松 扫描显示，体脂百分比下降(p&lt；0.03)，而 瘦体重(P&lt；0.03)和骨密度(腰椎+7%； 股骨粗隆+9%，P均<0.01)。数据表明，老年人的ERT 绝经后妇女改善代谢功能，并导致 身体成分发生了有利的变化。我们发现一个有利的风险/收益 高龄绝经后妇女的ERT比率。